Cardiovascular Morbidity During Treatment of Overactive Bladder With B3 Agonists
NCT02622555
·
clinicaltrials.gov ↗
COMPLETED
Status
221
Enrollment
OTHER
Sponsor class
Conditions
Overactive Bladder
Interventions
DRUG:
Mirabegron
Sponsor
Karolinska Institutet